Welcome: Guest | Register | Login |

Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical, Inc. for up to $2.63 Billion

Awardee Story Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical, Inc. for up to $2.63 Billion
Date: Mar 01, 2012
Author: Patricia Resende
Source: Mass High Tech

Drug discovery company Boston Biomedical Inc. announced today that it will be acquired by Japan-based Dainippon Sumitomo Pharma Co., Ltd. for up to $2.63 billion. DSP will pay $200 million upfront, $540 million in development milestone payments and up to $1.89 billion in sales milestone payments. The boards of directors of both companies unanimously approved the deal.

The Norwood-based company has a pipeline of drug candidates that target cancer stem cells including BBI608 and BBI503. The orally-administered BBI608 is ready for Phase 3 trials for colorectal cancer in North America and Phase1b and Phase 2 trials for multiple solid tumors. BBI608 targets both highly malignant cancer stem cells as well as heterogeneous cancer cells.

Boston Biomedical Chairman and CEO Chiang J. Li said in a statement that the deal was a “strategic transaction” that will be the best path to bring its cancer stemness inhibitors to patients.

The acquisition comes less than a year after Boston Biomedical signed a $15 million licensing deal with DSP for BBI608.

Once the acquisition is complete, Boston Biomedical will become a fully-owned subsidiary of DSP. Operations will continue in the Boston area, according to the company. The acquisition is scheduled to be completed in April.

Contact information

Innovation Development Institute, LLC

   45 Beach Bluff Avenue, Suite 300
     Swampscott,  MA 01907-1542

  Tel:  (781) 595-2920

  support@inknowvation.com